These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19647226)

  • 1. Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5.
    Xiao W; Hong H; Kawakami Y; Kato Y; Wu D; Yasudo H; Kimura A; Kubagawa H; Bertoli LF; Davis RS; Chau LA; Madrenas J; Hsia CC; Xenocostas A; Kipps TJ; Hennighausen L; Iwama A; Nakauchi H; Kawakami T
    Cancer Cell; 2009 Aug; 16(2):161-71. PubMed ID: 19647226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SPS affair: a complex tale of illicit proliferation.
    Braun BS; Shannon K
    Cancer Cell; 2009 Aug; 16(2):87-8. PubMed ID: 19647218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short Stat5-interacting peptide derived from phospholipase C-β3 inhibits hematopoietic cell proliferation and myeloid differentiation.
    Yasudo H; Ando T; Xiao W; Kawakami Y; Kawakami T
    PLoS One; 2011; 6(9):e24995. PubMed ID: 21949826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lyn- and PLC-beta3-dependent regulation of SHP-1 phosphorylation controls Stat5 activity and myelomonocytic leukemia-like disease.
    Xiao W; Ando T; Wang HY; Kawakami Y; Kawakami T
    Blood; 2010 Dec; 116(26):6003-13. PubMed ID: 20858858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical role for mast cell Stat5 activity in skin inflammation.
    Ando T; Xiao W; Gao P; Namiranian S; Matsumoto K; Tomimori Y; Hong H; Yamashita H; Kimura M; Kashiwakura J; Hata TR; Izuhara K; Gurish MF; Roers A; Rafaels NM; Barnes KC; Jamora C; Kawakami Y; Kawakami T
    Cell Rep; 2014 Jan; 6(2):366-76. PubMed ID: 24412367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
    Rocnik JL; Okabe R; Yu JC; Lee BH; Giese N; Schenkein DP; Gilliland DG
    Blood; 2006 Aug; 108(4):1339-45. PubMed ID: 16627759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.
    Wernig G; Gonneville JR; Crowley BJ; Rodrigues MS; Reddy MM; Hudon HE; Walz C; Reiter A; Podar K; Royer Y; Constantinescu SN; Tomasson MH; Griffin JD; Gilliland DG; Sattler M
    Blood; 2008 Apr; 111(7):3751-9. PubMed ID: 18216297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies.
    Freund P; Kerenyi MA; Hager M; Wagner T; Wingelhofer B; Pham HTT; Elabd M; Han X; Valent P; Gouilleux F; Sexl V; Krämer OH; Groner B; Moriggl R
    Leukemia; 2017 Oct; 31(10):2132-2142. PubMed ID: 28074064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stat5-deficient hematopoiesis is permissive for Myc-induced B-cell leukemogenesis.
    Wang Z; Medrzycki M; Bunting ST; Bunting KD
    Oncotarget; 2015 Oct; 6(30):28961-72. PubMed ID: 26338970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phospholipase C-β3 regulates FcɛRI-mediated mast cell activation by recruiting the protein phosphatase SHP-1.
    Xiao W; Kashiwakura J; Hong H; Yasudo H; Ando T; Maeda-Yamamoto M; Wu D; Kawakami Y; Kawakami T
    Immunity; 2011 Jun; 34(6):893-904. PubMed ID: 21683628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A negative role of SHP-2 tyrosine phosphatase in growth factor-dependent hematopoietic cell survival.
    Chen J; Yu WM; Bunting KD; Qu CK
    Oncogene; 2004 Apr; 23(20):3659-69. PubMed ID: 15116097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.
    Guasch G; Ollendorff V; Borg JP; Birnbaum D; Pébusque MJ
    Mol Cell Biol; 2001 Dec; 21(23):8129-42. PubMed ID: 11689702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.
    Yu WM; Daino H; Chen J; Bunting KD; Qu CK
    J Biol Chem; 2006 Mar; 281(9):5426-34. PubMed ID: 16371368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease.
    Li G; Miskimen KL; Wang Z; Xie XY; Brenzovich J; Ryan JJ; Tse W; Moriggl R; Bunting KD
    Blood; 2010 Feb; 115(7):1416-24. PubMed ID: 20008792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.
    Funakoshi-Tago M; Tago K; Abe M; Sonoda Y; Kasahara T
    J Biol Chem; 2010 Feb; 285(8):5296-307. PubMed ID: 20028972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phospholipase C-β in immune cells.
    Kawakami T; Xiao W
    Adv Biol Regul; 2013 Sep; 53(3):249-57. PubMed ID: 23981313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
    Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
    Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phospholipase C beta3 deficiency leads to macrophage hypersensitivity to apoptotic induction and reduction of atherosclerosis in mice.
    Wang Z; Liu B; Wang P; Dong X; Fernandez-Hernando C; Li Z; Hla T; Li Z; Claffey K; Smith JD; Wu D
    J Clin Invest; 2008 Jan; 118(1):195-204. PubMed ID: 18079968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling.
    Yu WM; Hawley TS; Hawley RG; Qu CK
    Oncogene; 2003 Sep; 22(38):5995-6004. PubMed ID: 12955078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
    Ueda F; Tago K; Tamura H; Funakoshi-Tago M
    J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.